Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 6/20 | 0.37 |
| ▸ | SPR | P35270 | 3/20 | 0.33 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.32 |
| ▸ | TYMS | P04818 | 2/20 | 0.31 |
| ▸ | CDK4 | P11802 | 1/20 | 0.30 |
| ▸ | CCND1 | P24385 | 1/20 | 0.30 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
| ▸ | TYK2 | P29597 | 1/20 | 0.30 |
| ▸ | FABP4 | P15090 | 1/20 | 0.30 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4023129 | 1.00 | PDE2A (0.37) | PDE2ASPRPI4KBTYMSCDK4 | |
| SCHEMBL13746667 | 0.88 | PDE2A (0.37) | PDE2ASPRPI4KBTYMSJAK2 | |
| SCHEMBL13747129 | 0.85 | TYMS (0.38) | PDE2ATYMS | |
| SCHEMBL4020404 | 0.84 | PDE2A (0.49) | PDE2API4KB | |
| SCHEMBL13746012 | 0.81 | PIK3CA (0.36) | PDE2ASPRPI4KBJAK2JAK1 | |
| SCHEMBL13746627 | 0.79 | USP1 (0.34) | PDE2ASPRTYMS | |
| SCHEMBL13746096 | 0.78 | PI4KB (0.35) | PDE2ASPRPI4KBTYMS | |
| SCHEMBL13746898 | 0.78 | HSD11B1 (0.39) | PDE2A | |
| SCHEMBL13746091 | 0.77 | DYRK1A (0.35) | PDE2ASPRFABP4FABP5 | |
| SCHEMBL4188382 | 0.76 | PDE2A (0.36) | PDE2ASPRJAK2JAK1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009100403-A1 | SUBSTITUTED ARYL PYRIMIDINONES | NEUROGEN CORPORATION (US) | 2009-08-13 | — | — | WO | disclosed |